An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Lampit

Chemical Namenifurtimox
Dosage FormTablets (oral; 30mg, 120mg)
Drug ClassAntiprotozoal
SystemBlood, Digestive, Cardiovascular, Nervous
CompanyBayer HealthCare Pharmaceuticals Inc.
Approval Year2020

Indication

  • Indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Lampit (nifurtimox) Prescribing Information. 2020Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
Document TitleYearSource
Prospective, historically controlled study to evaluate the efficacy and safety of a new pediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas' disease. 2020Bayer